United Kingdom Lipid Nanoparticle Market Size, Share, and COVID-19 Impact Analysis, By LNP (Liposomes, Nanostructured Lipid Carriers, Solid Lipid Nanoparticles, and Other LNP Type), By Molecule (mRNA, siRNA, and Other Molecule type), By Indication (Cancer, Infectious Diseases, Blood Diseases, and Other Indication), and United Kingdom Lipid Nanoparticle Market Insights, Industry Trend, Forecasts to 2035

United Kingdom Lipid Nanoparticle Market Insights Forecasts to 2035

• The United Kingdom Lipid Nanoparticle Market Size was estimated at USD 40.34 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 12.45% from 2025 to 2035
• The United Kingdom Lipid Nanoparticle Market Size is Expected to Reach USD 146.64 Million by 2035

According to a research report published by Spherical Insights & Consulting, the United Kingdom Lipid Nanoparticle Market is anticipated to reach USD 146.64 million by 2035, growing at a CAGR of 12.45% from 2025 to 2035. The rising incidence of persistent illnesses, including cancer and heart disease, combined with advancements in mRNA treatments, has driven the market for lipid nanoparticles.

Market Overview

The market for lipid nanoparticles (LNPs) in the UK is the area of the pharmaceutical and biotechnology sectors devoted to the study, creation, manufacturing, and usage of lipid-based nanoscale delivery systems. Therapeutic agents like mRNA, DNA, small molecules, and proteins are frequently encapsulated and delivered by lipid nanoparticles, which are tiny spherical carriers made of biocompatible lipids. This sector in the UK supports the development of innovative drug delivery systems, especially in gene therapy, vaccines, and oncology therapies. It includes a variety of activities, from clinical trials and university research to commercial-scale manufacture. Clinically sophisticated gene delivery methods are lipid nanoparticles. They are typically employed to carry nucleic acids, making them viable carriers for a number of pharmaceutical sector therapeutic choices. The production of LNP-based medications to deliver a range of therapeutic substances is the focus of numerous biotechnology and pharmaceutical businesses. Cancer and other illnesses are being treated with the help of nanoparticles. For the delivery of drugs for nucleic acid-based therapies, such as mRNA vaccines, these products have proven essential. These products are reportedly spherical vesicles made of ionizable lipids that contain RNA and DNA. The purpose of these items is to enhance the delivery of DNA and RNA agents.

Report Coverage

This research report categorizes the market for the United Kingdom lipid nanoparticle market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the United Kingdom lipid nanoparticle market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the United Kingdom lipid nanoparticle market.

Driving Factors

The market for United Kingdom lipid nanoparticle is primarily driven by a rising reliance on lipid nanoparticles (LNPs) for efficient drug delivery solutions, and developments in RNA treatments. Further driving breakthroughs is a robust academic and research and development ecosystem, as well as government funding for nanoscale innovation. Furthermore, the need for effective, targeted drug delivery platforms is increasing due to the rising incidence of cancer and chronic disorders, which makes LNPs a key area of emphasis for next-generation therapies. Additionally, the thriving biopharmaceutical industry and beneficial government regulations will increase. Moreover, the increasing demand for lipid nanoparticles due to precision medicine's expanding popularity has aided in the market's expansion.

Restraining Factors

Despite the substantial growth of this market, there are some hurdles, such as regulatory delays, high R&D expenses, and restricted access to specialized manufacturing facilities, especially for smaller hospitals and biotech companies. Additionally, stakeholders remain cautious due to worries about the long-term safety, environmental impact of nanoparticles, and public awareness.

Market Segmentation

The United Kingdom lipid nanoparticle market share is classified into LNP type, molecule, and indication.

• The liposomes segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The United Kingdom lipid nanoparticle market is differentiated by LNP into liposomes, nanostructured lipid carriers, solid lipid nanoparticles, and other LNP type. Among these, the liposomes segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The widespread usage is due to excellent delivery systems for chemotherapeutics, vaccines, and antifungal medications because of their biocompatibility, capacity to encapsulate hydrophilic and lipophilic medications, and enhanced pharmacokinetics. Liposome-based formulations are becoming more and more popular due to the growing need for controlled-release and targeted drug delivery methods, as well as increased R&D expenditures associated with nanomedicine.

• The siRNA segment held a significant share in 2024 and is expected to grow at a rapid pace over the forecast period.

The United Kingdom lipid nanoparticle market is divided by molecule mRNA, siRNA, and other molecule type. Among these, the siRNA segment held a significant share in 2024 and is expected to grow at a rapid pace over the forecast period. This is because of their capacity to encapsulate and shield these sensitive molecules, which need effective and targeted delivery systems to reach particular cells and tissues without deteriorating. The market is growing because of the growing need for LNPs specifically designed for siRNA delivery brought on by advancements in research on uncommon disorders, cancer, and genetic diseases.

• The infectious diseases segment accounted for a significant share in 2024 and is anticipated to grow at a rapid pace during the forecast period.

The United Kingdom lipid nanoparticle market is segmented by indication into cancer, infectious diseases, blood diseases, and other indication. Among these, the infectious diseases segment accounted for a significant share in 2024 and is anticipated to grow at a rapid pace during the forecast period. This is because of is easier for the mRNA to reach cells and shields it from deterioration within the body. The need for LNP has grown dramatically as more nations implement immunization campaigns, for instance, the treatment of viral infections like influenza and HIV.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom lipid nanoparticle market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Hone Bio
• NeoVac
• NanoVation Therapeutics (NTx UK)
• Particle Works (partner of NTx)
• Centre for Process Innovation (CPI)
• Inside Therapeutics / Analytik
• Others

Recent Developments:

• In February 2025, in the first application of this technique on LNPs in the UK, researchers employed cryo-OrbiSIMS to examine the multilayer structure of lipid nanoparticles at nanoscale precision. These realizations facilitate the logical development of safer and more effective LNP formulations and enhance quality control as the product is scaled up from laboratory to clinic.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at United Kingdom, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the United Kingdom lipid nanoparticle market based on the below-mentioned segments:

United Kingdom Lipid Nanoparticle Market, By LNP Type

• Liposomes
• Nanostructured lipid carriers
• Solid lipid nanoparticles
• Other LNP type

United Kingdom Lipid Nanoparticle Market, By Molecule

• mRNA
• siRNA
• Other Molecule type

United Kingdom Lipid Nanoparticle Market, By Induction 

• Cancer
• Infectious Diseases
• Blood Diseases
• Other Indication